Strain Independent Therapeutic Antibodies for Influenza

DESCRIPTION provided by applicant Trellis Bioscienceandapos s CellSpotandquot technology for identification of rare human antibodies with high specificity and affinity against multiple antigen has enabled discovery of highly efficacious strain independent antibodies to Respiratory Syncytial Virus and to Cytomegalovirus We have now applied CellSpot to isolate two native human antibodies with broad reactivity to Group and Group influenza A strains respectively Both of these antibodies have now been shown to have in vivo efficacy In addition we have isolated a human antibody with in vitro activity against Influenza B We propose to advance these therapeutic candidates to IND stage including additional neutralization studies in vitro and in vivo manufacturing toxicity and PK studies The resulting clinical candidates are expected to provide potent post infection antiviral activity against all currently circulating strains and effective prophylaxis against any emerging pandemic strain PUBLIC HEALTH RELEVANCE This project will advance the development of broad spectrum therapeutic antibodies to the influenza virus HA protein The antibodies will have the ability to protect animals and ultimately humans during influenza infection and will be developed as a new therapeutic agent for this disease with the end result of this work being a fully characterized IND candidate